Skip to content

CESI With Low Dose Lidocaine and Transient Weakness

Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03127137
Enrollment
123
Registered
2017-04-25
Start date
2018-08-01
Completion date
2019-06-15
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Radiculitis, Pain

Brief summary

Cervical radicular pain is relatively common, often treated with epidural steroid injection (ESI), when conservative treatments like oral analgesics, physical therapy and activity modification have failed. There are no universal clinical practice guidelines for the use of diluents when CESI are performed. Interlaminar CESI may be performed with or without the use of local anesthetics, due to training bias or theoretical concerns of weakness. CESI without the benefit of local anesthetic as a steroid diluent increases the latency of pain relief and may decrease diagnostic information immediately after a CESI with regard to pain generators responsible for symptoms, and may potentially decrease patient satisfaction. By evaluating the effects of local anesthetic as a diluent during interlaminar cervical ESI, we will enhance the safety of this treatment with regard to expectations of objective motor weakness as well as post procedure pain control and patient satisfaction in the recovery phase after the injection procedure. Research Question: Does lidocaine versus saline as a steroid diluent effect objective upper extremity strength following cervical epidural steroid injection in patients being treated for cervical radiculitis? Null Hypothesis: Cervical epidural steroid injections that include local anesthetic as a diluent have no effect on objective upper extremity strength following the injection. We hypothesized that cervical epidural lidocaine will cause an objective decrease in strength in functional movements of the upper extremity.

Detailed description

Experimental Groups: Prospective, randomized, controlled, double blinded trial in patients undergoing CESI for symptoms of cervical radiculitis. Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc). Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc). Adults who are eligible to have a CESI with triamcinolone for treatment of cervical radiculitis at the Northwestern Anesthesiology Pain Medicine Center will be approached by authorized research personnel prior to a patient's CESI is performed and will obtain informed consent from patients who agree to participate. In every subject (Group 1 and Group 2) a pre-procedure NRS pain score, and presence of subjective or objective symptoms of UE weakness will be recorded. Bilateral handgrip, wrist extension, elbow flexion, and elbow extension strength (myotomes C5-T1) will be measured by a trained research assistant prior to the injection procedure using a handheld JAMAR® PLUS+ digital dynamometer (Sammons Preston, Bollingbrook, IL) for hand grip strength and a push/pull handheld hydraulic dynamometer (Balego and Associates Inc., St. Paul, MN) for arm strength assessment. Three baseline strength measurements will be recorded for each strength test. Measurements will be taken prior to and 30 minutes following the injection procedure. Patients in Group #1 and Group #2 will also be queried with the Upper Extremity Functional Index (UEFI) before the injection procedure and again 1 day after the procedure (administered via telephone). For Group 1 and Group 2, patients will be randomized to treatment group based on a random computer-generated schedule. Participants will be blinded to the group to which they are randomized. All standard procedures for CESIs will be followed as is standard practice including time out, skin prep, hemodynamic monitoring, image guidance etc. Per randomization, triamcinolone acetonide 80 mg (Kenalog) (E. R. Squibb & Sons Limited, Uxbridge UK) will be combined with 2mL Lidocaine 1% or 2 mL preservative free saline and will be injected during the CESI procedure. In all cases, the total injectate volume will be 4 mL in all cases. All injections will be image guided with fluoroscopy, as is the current standard practice. Fluoroscopy time will be recorded. The participant will be discharged from the clinic with written discharge instructions (current standard practice). Participants will be telephoned by clinic personnel 1 day after the CESI to assess for subjective weakness in the hands or arms as well as any other adverse reactions. As above, the Upper Extremity Functional Index will be administered at this time.

Interventions

DRUGExperimental Group 1 triamcinolone and lidocaine

Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)

DRUGExperimental Group 2 triamcinolone and saline

Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participant will be blinded to group assignment. Outcome assessor will also be blinded to the randomization.

Intervention model description

Prospective Randomized Controlled Trial using control arm plus 2 arm experimental (placebo and active drug)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients ages 18 years or older who will undergo CESI for treatment of cervical radiculitis

Exclusion criteria

* Patient refusal * Lack of consent * Any contraindication to CESI * Inability to communicate with staff or to participate in follow up * Inability to perform handgrip or arm strength testing * Cervical spinal cord lesions * Cerebrovascular, demyelinating or other neuromuscular muscular disease * Patient request for or requirement of conscious sedation for the injection procedure * Pregnancy * Breast feeding * Sensitivity to amides * History of allergy to local anesthetics

Design outcomes

Primary

MeasureTime frameDescription
Change in Strength in Both Groups After CESI.30 minutes after the CESI procedureChange in strength in both groups greater than or equal to 20% weakness in one or more myotomes 30 minutes after CESI using a hand held Dynamometer.

Secondary

MeasureTime frameDescription
Number of Participants With Pain Reduction Post Procedure30 minutes after the CESI procedure.A greater than or equal to 50% reduction in change in average pain score before and after the CESI procedure.

Countries

United States

Participant flow

Pre-assignment details

159 subjects were assessed for eligibility. 27 declined to participate. 2 could not perform pre-study strength testing. 7 requested sedation for the injection.

Participants by arm

ArmCount
Experimental Group 1 With Lidocaine
Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc) Experimental Group 1 triamcinolone and lidocaine: Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
60
Experimental Group 2 With Saline
Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc) Experimental Group 2 triamcinolone and saline: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
60
Total120

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyMalfunction in electronic data collection10
Overall StudyPost procedure testing could not be obtained01
Overall StudyRequested sedation after consent10

Baseline characteristics

CharacteristicExperimental Group 2 With SalineTotalExperimental Group 1 With Lidocaine
Age, Continuous
Years
56.3 years
STANDARD_DEVIATION 13.4
56.5 years
STANDARD_DEVIATION 13.6
56.6 years
STANDARD_DEVIATION 14
Body Mass Index (kg/m^2)29.2 BMI (kg/m^2)
STANDARD_DEVIATION 6.1
27.8 BMI (kg/m^2)
STANDARD_DEVIATION 5.5
26.5 BMI (kg/m^2)
STANDARD_DEVIATION 4.9
Number of Participants with radicular pain based on myotome location
c 5 myotome
13 Participants28 Participants15 Participants
Number of Participants with radicular pain based on myotome location
c 6 myotome
30 Participants59 Participants29 Participants
Number of Participants with radicular pain based on myotome location
c 7 myotome
9 Participants21 Participants12 Participants
Number of Participants with radicular pain based on myotome location
c 8 myotome
1 Participants1 Participants0 Participants
Number of Participants with radicular pain based on myotome location
Missing myotome location
7 Participants11 Participants4 Participants
Number of participants with unilateral or bilateral symptoms
Bilateral
11 participants24 participants13 participants
Number of participants with unilateral or bilateral symptoms
Missing
1 participants2 participants1 participants
Number of participants with unilateral or bilateral symptoms
Unilateral
47 participants94 participants47 participants
Numerical rating score(NRS) for pain5.4 score on a scale
STANDARD_DEVIATION 2.4
5.2 score on a scale
STANDARD_DEVIATION 2.3
4.9 score on a scale
STANDARD_DEVIATION 2.3
Physical exam- weakness in any myotome, freq (%)
Missing data
1 participants4 participants3 participants
Physical exam- weakness in any myotome, freq (%)
No weakness
47 participants101 participants54 participants
Physical exam- weakness in any myotome, freq (%)
Yes weakness
12 participants15 participants3 participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
60 participants120 participants60 participants
Sex: Female, Male
Female
26 Participants56 Participants30 Participants
Sex: Female, Male
Male
34 Participants64 Participants30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 600 / 60
other
Total, other adverse events
6 / 607 / 60
serious
Total, serious adverse events
0 / 600 / 60

Outcome results

Primary

Change in Strength in Both Groups After CESI.

Change in strength in both groups greater than or equal to 20% weakness in one or more myotomes 30 minutes after CESI using a hand held Dynamometer.

Time frame: 30 minutes after the CESI procedure

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Experimental Group 1 With LidocaineChange in Strength in Both Groups After CESI.Yes, greater or equal to 20% weakness in greater or equal to 1 or more myotome25 Participants
Experimental Group 1 With LidocaineChange in Strength in Both Groups After CESI.No, greater or equal to 20% weakness in greater or equal to 1 or more myotome35 Participants
Experimental Group 2 With SalineChange in Strength in Both Groups After CESI.Yes, greater or equal to 20% weakness in greater or equal to 1 or more myotome30 Participants
Experimental Group 2 With SalineChange in Strength in Both Groups After CESI.No, greater or equal to 20% weakness in greater or equal to 1 or more myotome30 Participants
p-value: 0.05Fisher Exact
Secondary

Number of Participants With Pain Reduction Post Procedure

A greater than or equal to 50% reduction in change in average pain score before and after the CESI procedure.

Time frame: 30 minutes after the CESI procedure.

Population: Patients whose baseline and post-NRS scores were both zero were excluded from this analysis.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
Experimental Group 1 With LidocaineNumber of Participants With Pain Reduction Post ProcedureExperienced greater than or equal to 50% reduction in pain19 Participants
Experimental Group 1 With LidocaineNumber of Participants With Pain Reduction Post ProcedureLess than 50% reduction in pain40 Participants
Experimental Group 2 With SalineNumber of Participants With Pain Reduction Post ProcedureExperienced greater than or equal to 50% reduction in pain12 Participants
Experimental Group 2 With SalineNumber of Participants With Pain Reduction Post ProcedureLess than 50% reduction in pain45 Participants
95% CI: [0.82, 2.86]

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026